Scholar Rock wins FDA approval for first drug to target SMA muscle loss

The Food and Drug Administration has approved Isembyld, developed by Scholar Rock, as the first drug to target muscle loss directly in patients with spinal muscular atrophy, according to STAT News.

Existing SMA therapies work by addressing the disease’s underlying genetic cause, correcting the production of the SMN protein that motor neurons need to survive. Isembyld takes a different approach, acting on muscle tissue itself rather than the nerve cells whose degeneration drives the disease. In the late-stage clinical trial supporting approval, researchers combined Isembyld with an SMN2-targeting drug, one of the existing genetic-pathway therapies, and found that young patients’ motor skills improved after a year of treatment when the two drugs were used together.

STAT News reports that the approval establishes a complementary treatment avenue for SMA, a disease that causes progressive muscle weakness and, in its most severe forms, has historically proven fatal in early childhood. Because Isembyld works through a distinct biological mechanism from currently available therapies, it can be layered onto existing SMN-directed treatment rather than replacing it, giving physicians an additional tool for patients who still experience muscle loss despite genetic-pathway treatment.

The approval marks Scholar Rock’s first FDA-cleared product and the first drug of its kind to reach the SMA treatment landscape, according to the report.